Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19[1].
Molecular Weight:
(146.22 kDa)
Purity:
95.00
CAS Number:
[2444308-95-4]
Target:
Angiotensin-converting Enzyme (ACE),SARS-CoV
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted